Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CNR1 | P21554 | 10/20 | 0.57 |
| ▸ | CNR2 | P34972 | 8/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10654346 | 0.87 | PTGS2 (1.00) | PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL15140969 | 0.86 | PTGS2 (0.97) | PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL21925060 | 0.86 | PTGS2 (0.97) | PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL17509809 | 0.86 | PTGS2 (0.97) | PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL17509775 | 0.86 | PTGS2 (0.97) | PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL23462775 | 0.86 | PTGS2 (0.97) | PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL16932836 | 0.86 | PTGS2 (0.97) | PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL10652400 | 0.86 | PTGS2 (0.97) | PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL17509787 | 0.86 | PTGS2 (0.97) | PTGS2CYP3A4CNR1CNR2 | |
| SCHEMBL28946091 | 0.86 | PTGS2 (0.73) | PTGS2CYP3A4CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390332-B1 | UNCATALYSED ADDITION REACTIONS | JOHNSON MATTHEY PLC (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-6867335-B2 | Uncatalysed addition reactions | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2005-03-15 | — | — | US | disclosed |
| US-20040210076-A1 | Uncatalysed addition reactions | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2004-10-21 | — | — | US | disclosed |
| EP-1390332-A1 | UNCATALYSED ADDITION REACTIONS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002096846-A1 | UNCATALYSED ADDITION REACTIONS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210076-A1 | Uncatalysed addition reactions | SQLE, XDH, DCXR | PTGS2 751/4885CYP3A4 296/4885CNR1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.